Immunitybio Inc (IBRX) Stock Price & News - Google Finance

Get the latest Immunitybio Inc (IBRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

$100
OFF

IBRX Stock Price | ImmunityBio Inc. Stock Quote (U.S.: Nasdaq ...

2 weeks from now

2 days ago · ImmunityBio Inc (IBRX) Announces $100 Million Public Offering of Common Stock Dec. 12, 2024 at 8:02 a.m. ET on GuruFocus.com 12 Health Care Stocks Moving In …

marketwatch.com

$100
OFF

ImmunityBio, Inc. (IBRX) Stock Price, Quote & News - Stock Analysis

2 weeks from now

3 days ago · D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering. CULVER CITY, Calif., Dec. 12, …

stockanalysis.com

$2.32
OFF

ImmunityBio (IBRX) Stock Price, News & Analysis - MarketBeat

2 weeks from now

2 days ago · Get The Latest IBRX Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. ... ImmunityBio (IBRX) Stock Price, News & Analysis $2.32 …

marketbeat.com

38%
OFF

BTIG Initiates Coverage Of ImmunityBio (IBRX) With Buy ... - Nasdaq

2 weeks from now

Dec 23, 2024 · Analyst Price Forecast Suggests 499.38% Upside. As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low …

nasdaq.com

$13.58
OFF

ImmunityBio (IBRX) Stock Forecast & Price Target - MarketBeat

2 weeks from now

2 days ago · According to the 4 analysts' twelve-month price targets for ImmunityBio, the average price target is $13.58. The highest price target for IBRX is $30.00, while the lowest price target …

marketbeat.com

18%
OFF

IBRX Stock Price & Charts | ImmunityBio

2 weeks from now

In depth view into IBRX (ImmunityBio) stock including the latest price, news, dividend history, earnings information and financials. ImmunityBio Inc (IBRX) 2.655 -0.18 ( -6.18% ) USD | …

ycharts.com

22%
OFF

ImmunityBio (IBRX) P/E Ratio: Current & Historical Analysis

2 weeks from now

The P/E ratio for ImmunityBio (IBRX) is -2.62 as of Jan 14, 2025.This represents a decrease of-48.22% compared to its 12-month average P/E ratio of-5.06.A higher P/E ratio suggests that …

public.com

2%
OFF

ImmunityBio (NASDAQ:IBRX) Trading Down 5.2% - What's Next?

2 weeks from now

2 days ago · ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report)'s stock price traded down 5.2% during trading on Tuesday . The company traded as low as $2.32 and last traded at …

marketbeat.com

FAQs about Immunitybio Inc (IBRX) Stock Price & News - Google Finance Coupon?

Does IBRX have company insights?

IBRX does not have Company Insights Find the latest ImmunityBio, Inc. (IBRX) stock quote, history, news and other vital information to help you with your stock trading and investing. ...

What is the price target for immunitybio (IBRX)?

The highest price target for IBRX is $30.00, while the lowest price target for IBRX is $4.75. The average price target represents a forecasted upside of 578.71% from the current price of $2.56. Enter your email address to receive the latest news and analysts' ratings for ImmunityBio and its competitors. ...

Where is immunitybio headquartered?

ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA. IBRX | Complete ImmunityBio Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ...

What is immunitybio (IBRX)?

Market Cap: $1.94 billion ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory. ...

Does immunitybio (IBRX) have a short interest %?

NEW YORK , July 25, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ImmunityBio, Inc. (NASDAQ: IBRX) breached their ... IBRX has a short interest % of the float of 33%, superior to GME at 21%. Investors should keep an eye on it for short squeeze-fueled volatility. ...

Does immunitybio (IBRX) have a Marketing Authorization Application?

ImmunityBio, Inc. (NASDAQ:IBRX) plans to expand its product globally and submitted a Marketing Authorization Application (MAA) for ANKTIVA in 30 countries in the EU in fiscal Q4 2024. It also submitted ANKTIVA for potential approval to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK. ...